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Introduction
Although chemotherapy has led to improvement in the
survival and quality of life of cancer patients, the major-
ity of these patients eventually develop progressive disease
after initially responding to treatment. Drug resistance
represents a major obstacle to improving the overall
response and survival of cancer patients. Tumors show-
ing resistance to chemotherapy may present this char-
acter before encountering any chemotherapeutic drugs,
being intrinsically resistant, such as melanoma and hep-
atoma. More tumors, however, may initially be sensitive
to therapy and later become insensitive to similar drugs,
having acquired resistance. Ovarian cancer is a prime
example of these tumors. The phenomenon of acquired
tumor resistance to chemotherapeutic drugs has been
recognized for decades. It is known that several cell
membrane transporter proteins are responsible for the
resistance to many commonly used chemotherapeutic
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SUMMARY
Chemotherapy is one of the principal modes of treatment for cancer patients. Clinically, many tumors present a
satisfactory response when they are first exposed to the chemotherapeutic drugs. However, drug resistance occurs
sooner or later in these tumors, and the majority of the patients develop progressive disease. The mechanisms of
treatment failure of chemotherapeutic drugs have been well studied. Via a unique protection system, i.e. multidrug
resistance (MDR), the cancer cells can escape the toxic effect of most commonly used cancer drugs in spite of
their different chemical structures and different mechanisms of intracellular activity. There are two classes of
transporter proteins at the cellular surface which are responsible for MDR in tumors. One is the adenosine
triphosphate-binding cassette transporter superfamily, which is an energy-requiring efflux pump with the func-
tion of extruding toxic chemotherapeutic drugs from the cancer cells. The other is the solute carrier transporter
superfamily, which mediates the cellular uptake of anticancer drugs, and drug resistance may result from decreased
activity of these transporters. Although transporters of MDR are responsible for the tumor resistance to many
chemotherapeutic drugs currently used in cancer therapy, the mechanisms of resistance to platinum-based anti-
tumor agents are through different pathways. In this article, the mechanisms of MDR transporters mediating
resistance to the commonly used chemotherapeutic drugs and to platinum-based agents are reviewed. Finally,
with the finding of cancer stem cells in more and more solid tumors, it is recognized that the cancer stem cell is
spared along with its normal tissue stem cell counterparts with very subtle differences. One characteristic of the
normal tissue stem cell is the self-protection ability through innate MDR transporters. Therefore, the essential self-
protection property is also present in the cancer stem cells. The quiescent tumor stem cell with constitutive MDR
is the main barrier to therapy. Successful cancer therapy will depend on the ability to discern the subtle differences
between the tumor and normal stem cells so that approaches can be developed to eliminate the tumor stem
cells without excessive toxicity to normal stem cells. [Taiwan J Obstet Gynecol 2009;48(3):239–244]
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drugs by affecting disposition of these drugs in the
tumor cells. However, resistance to another group of
chemotherapeutic drugs, i.e. platinum (Pt)-based anti-
cancer agents, is caused by different mechanisms. In this
article, a concise review of the mechanisms of chemo-
therapeutic drug resistance is presented.
Multidrug Resistance (MDR)
MDR is a system of protection of the cell population
against numerous compounds, including drugs char-
acterized by different chemical structures and by differ-
ent mechanisms of intracellular activity. There are two
classes of membrane transporter proteins which influ-
ence the pharmacokinetics of drugs in cells, and their
changes are responsible for MDR in tumors. One is the
adenosine triphosphate-binding cassette (ABC) trans-
porter superfamily, which is frequently associated with
decreased cellular accumulation of hydrophobic anti-
cancer chemotherapeutic drugs by extruding them from
cells when these drugs diffuse down a concentration gra-
dient into the cells. The other transporter superfamily,
solute carrier transporters, commonly increases chemo-
sensitivity by mediating the cellular uptake of hydro-
philic anticancer drugs [1]. Chemotherapeutic drug
resistance may result from decreased activity of these
uptake transporters.
Proteins of the ABC family are characterized by 
the presence of a cytoplasmic adenosine triphosphate
(ATP)-binding domain with a specific structure, i.e. a
nucleotide-binding domain (NBD). It functions to har-
vest energy from ATP hydrolysis so that the transporters
can act as efflux pumps to remove various intracellu-
lar chemotherapeutic drugs. ABC transporters contain
another membrane-spanning component, the trans-
membrane domain (TMD). It is composed, in most
cases, of six membrane-spanning helices. The TMD
offers the binding site for substrates or chemothera-
peutic drugs for translocation from the cytoplasm to
the cell membrane.
Human proteins of the ABC family are divided into
seven subfamilies (class A to G) based on the domain
organization, namely the number and combination of
TMDs and NBDs. In total, there are 49 protein mem-
bers in this family, but only three are well known for
their MDR [2]. They are P-glycoprotein (P-gp; MDR1/
ABCB1), MDR-associated protein (MRP1; ABCC1), and
breast cancer resistance protein (BCRP; ABCG2). All
three extrude various hydrophobic compounds and,
therefore, have broad and, to a certain extent, overlap-
ping substrate specificities in transporting the major
drugs currently used in cancer chemotherapy. In addition,
MRP1 and ABCG2 can expel xenobiotics and intracel-
lularly formed metabolic products.
P-glycoprotein (P-gp, MDR1, ABCB1)
P-gp was the first identified ABC transporter and is the
product of the human ABCB1 gene, localized to chro-
mosome 7q21. P-gp is a membrane-bound glycoprotein
consisting of 1,280 amino acids. According to sequence
analysis, P-gp is constructed in the form of a so-called
full transporter, i.e. it is composed of two homologous
half transporters with each one containing a TMD and
NBD. The two TMDs and two NBDs of P-gp are ar-
ranged in the sequence of TMD1-NBD1-TMD2-NBD2
with a linker region connecting the two half trans-
porters [3]. The linker region plays a critical role in
ensuring proper interaction of the two subunits. With
deletion of the central core of the linker region, a P-gp
protein is still expressed at the cell membrane at levels
similar to the wild-type protein, but is not functional
for either transport or drug-stimulated adenosine tri-
phosphatase activity [4]. It is suggested that the linker
region is most likely to provide communication be-
tween the two ATP sites of NBD. P-gp transports neu-
tral and cationic hydrophobic compounds, such as
the natural products vinblastine, vincristine, doxoru-
bicin, daunorubicin, actinomycin D, etoposide, and
paclitaxel. Drug transport by P-gp is coupled to two
hydrolyses of ATP. The first ATP hydrolysis, converting
ATP to adenosine diphosphate (ADP), is essential for
nucleoside diphosphate trapping into P-gp to form a
transition-state intermediate of the P-gp complex.
Following the first ATP hydrolysis, the drug is extruded
from P-gp and the ADP dissociates from the complex.
An additional molecule of ATP then binds to the alter-
nate ATP site on P-gp. It is hydrolyzed and the disasso-
ciation of ADP allows the conformation of P-gp to be
restored to its original state, to initiate the next cycle
of drug transport [5].
P-gp expression is regulated by various factors. Muta-
tion of the p53 gene and overexpression of the p63
gene and/or the p73 gene in certain tumors may facili-
tate P-gp expression. ABCB1 promoter activation by a
nuclear protein, MDR1 promoter-enhancing factor, or
a component of the multiprotein complex, RNA helicase
A, may upregulate P-gp expression. Epigenetic methy-
lation, in contrast, results in silence of ABCB1. Other
factors which activate P-gp expression include random
chromosomal rearrangement, stress signals, such as
heat shock, inflammation and hypoxia, exposure to xeno-
biotics, toxic metabolites, ultraviolet radiation, and glu-
cocorticoids. Chromatin-modifying enzymes, like histone
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acetylases and histone deacetylases, were found to be
involved in the regulation of the ABCB1 gene [3].
Despite 30 years of P-gp research, there is still no
clear therapeutic strategy to overcome the actions of
this classical drug efflux pump in tumors. Recently, it
was found that the expression of a major glycosamino-
glycan in the extracellular matrix, hyaluronan (HA),
and its receptor, CD44, a cell surface marker for both
normal and cancer stem cells, are tightly linked to MDR and
tumor progression. In breast and ovarian cancer cell
lines, HA-CD44 interaction may activate the stem cell
marker, Nanog, which can further activate the expres-
sion of pluripotent stem cell regulators (Rex1 and Sox2)
and Stat-3-mediated ABCB1 gene expression. In addition,
HA-CD44 binding may form a complex with ankyrin,
the downstream effector of CD44. This complex for-
mation results in an efflux of chemotherapeutic drugs.
Anti-CD44 antibody not only blocks HA-CD44 binding
but also inhibits ABCB1-mediated efflux activity. Thus,
anti-CD44 antibody may be used in combination with
chemotherapy to enhance chemosensitivity [6].
MDR-associated Protein 
(MRP1, ABCC1)
The human MRP1 gene is mapped to chromosome
16p13.1. It encodes a membrane-bound glycoprotein
consisting of 1,531 amino acids. This protein has a
similar topologic structure to that of P-gp. However, in
addition to the two half transporters connected by a
linker region L1 as in P-gp, MRP1 protein contains an
extra N-terminal segment, i.e. TMD0, which connects
TMD1 with a L0 linker region. The L0 linker region is
essential for drug transport, whereas TMD0 is not
required for transport [7].
Although MRP1 also requires two ATPs as the
energy source to transport chemotherapeutic drugs, the
mechanism in the cycle of transportation is somewhat
different from that of P-gp. In P-gp, the functions of the
two NBDs are “equal”, and the two ATP-binding sites
operate randomly but alternately. In MRP1, the func-
tion of NBD1 and NMD2 is nonequivalent, i.e. NBD1
has higher affinity than NBD2 for ATP. Therefore, when
the substrate binds to TMDs of MRP1, the conforma-
tional change of MRP1 protein first induces ATP bind-
ing at NBD1. It then further alters the conformation of
the protein and enhances ATP binding at NBD2.
When both NBD1 and NBD2 are occupied by the two
ATPs simultaneously, the bound substrate is trans-
ported out of the cell. After substrate extrusion, the
ATP bound at NBD2 is hydrolyzed first. The release of
ADP and inorganic phosphate from NBD2 partially
brings the MRP1 protein back to its original conforma-
tion, and facilitates the dissociation of ATP bound at
NBD1. Subsequent release of ADP and inorganic phos-
phate from NBD1 returns the MRP1 protein to its orig-
inal conformation.
MRP1 is expressed almost ubiquitously in many
different organs and cell types. Unlike P-gp, which is
invariably located in the apical membranes of epithelial
cells, MRP1 is located basolaterally and tends to pump
drugs into the body, rather than excrete them into the
bile, urine or gut. Cells overexpressing MRP1 protein
are resistant to a wide variety of anticancer drugs, e.g.
doxorubicin, epirubicin, vinblastine, vincristine, and
etoposide. However, MRP1 cannot transport the unmodi-
fied anticancer drugs without the presence of glu-
tathione (GSH). This implies that MRP1 may co-transport
the anticancer drugs with GSH, or GSH may bind 
to the MRP1 protein to enhance the transport of 
these hydrophobic anticancer drugs across biological
membranes [7].
Until now few MRP1-specific inhibitors have been
developed. The lack of success of clinical trials attempt-
ing to reverse P-gp-mediated drug resistance left many
hesitant to attempt studies to inhibit MRP1 clinically.
Breast Cancer Resistance Protein 
(BCRP, ABCG2)
The ABCG2 gene is localized to chromosome 4q21–
4q22. It encodes a plasma membrane glycoprotein of
655 amino acids. This gene was first cloned from 
a heavily drug-selected breast cancer cell line (MCF-7/
AdrVp) and was named breast cancer resistance 
protein (BCRP) [8].
Compared with P-gp and MRP1, ABCG2 is a half
transporter in structure. It contains only one TMD and
one NBD and shows a reverse domain arrangement,
i.e. NBD-TMD sequence. Two ABCG2 molecules form
a functioning homodimer by a disulfide (S-S) bridge
so that the ABCG2 can have two NBDs and two TMDs
for drug transportation [3].
ABCG2 is physiologically expressed in a variety of
tissues, most abundantly in the liver and intestinal
epithelium, the placenta, the blood–brain barrier, and
various stem cells. In tumors, overexpression of ABCG2
was documented in drug-selected cell lines from ovary,
lung, breast, colon, and gastric cancer. Clinically, the
chemotherapy response rate in patients with non-small
cell lung cancer was found to be correlated with ABCG2
expression [3].
The substrate transport and ATP cleavage cycle of
ABCG2 has not yet been investigated in as much detail
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as for P-gp or MRP1, but it is speculated to have no
major differences in the basic steps. ABCG2 substrates
include many kinds of chemotherapeutic drugs and
some molecularly targeted drugs, such as mitoxantrone,
topotecan, irinotecan, methotrexate, doxorubicin, epiru-
bicin, etoposide, gefitinib, and imatinib.
The expression of ABCG2 may be controlled by sev-
eral factors. Sex hormones, such as estrogen, proges-
terone and testosterone, were shown to exert an effect
on its expression, but conflicting data exist. ABCG2
expression is upregulated in the mammary gland during
lactation. In a multiple myeloma system and a renal car-
cinoma system, ABCG2 promoter hypermethylation was
linked to a decrease in ABCG2 expression. In addition,
hypoxia can regulate ABCG2 expression. It was sug-
gested that stem cells or tumor cells in hypoxic envi-
ronments may be protected from chemotherapeutic
agents because of increased levels of ABCG2 induced
by hypoxia [9]. The list of reported ABCG2 inhibitors
has been growing rapidly. However, none of them has
been used in a clinical setting.
Mechanisms of Resistance to Pt-based
Antitumor Agents
Although P-gp, MRP1, and ABCG2 are responsible for
tumor resistance to many chemotherapeutic drugs cur-
rently used in cancer therapy, they play no roles in
resistance to Pt-based antitumor agents such as cis-
platin, carboplatin, and oxaliplatin.
Pt-based antitumor agents are taken up into the cells
through a member of the solute carrier transporter
superfamily, hCtr1, which is also a copper transporter
at the cell membrane. There are three pathways for Pt
after it is taken up into the cells. Pt can be exported by
the copper efflux transporters, ATP7A and ATP7B. It
may also interact with GSH in the cytoplasm to form
Pt(GS)2 complex and be eliminated by an ABC trans-
porter, MDR-associated protein MRP2. Finally, a frac-
tion of Pt may enter the nucleus and form Pt-DNA
adducts [10]. The Pt atom of cisplatin in the Pt-DNA
adducts binds covalently to the N-7 position of pu-
rines in the DNA to form 1,2- or 1,3-intrastrand cross-
links, and interstrand cross-links [11]. However, 85–90%
of DNA lesions caused by cisplatin are intrastrand
cross-links.
DNA damage caused by cisplatin is recognized by
DNA damage recognition proteins, such as high mobil-
ity group proteins (HMG1 and HMG2) and mismatch
repair complexes (hMSH2 or hMutSα), which transduce
DNA damage signals to various downstream effectors.
Cell death or cell survival after DNA damage depends
on the relative intensity of the signals generated and
the crosstalk between the effectors involved. Among
these effectors, the p53 tumor suppressor gene plays 
a central role in determining the final fate of the cell.
DNA damage recognition proteins activate the mitogen-
activated protein kinase signal transduction pathway,
which then activates the function of p53 and causes cell
cycle arrest at the G2/M checkpoint for DNA repair. 
If the DNA damage is too excessive to repair, apoptosis
occurs through the Bax and caspase system. In addition,
DNA damage may also result in apoptosis through the
p53-related gene, the p73 gene [12].
The regulation of Pt transport in cells is a complex
network of regulation systems. It includes the follow-
ing proteins which are responsible for cisplatin 
transportation:
1. Expression of hCtr1, ATP7A and ATP7B, which are
regulated by intracellular copper homeostasis.
Recent studies have shown that increased expres-
sion of ATP7A mediates resistance to cisplatin, car-
boplatin, and oxaliplatin in ovarian cancer cells and
is associated with poor survival in ovarian cancer
patients [13,14].
2. Other factors which affect intracellular copper
availability, such as copper-binding proteins. The
cellular thiol-containing proteins (e.g. metalloth-
ioneins and GSH) bind not only copper but also Pt;
therefore, their levels in cells may influence the effi-
cacies of Pt drugs. It has been observed that increased
intracellular concentration of GSH may result in
inactivation of cisplatin because of increased for-
mation of Pt(GS)2 and decreased Pt-DNA adduct
formation.
3. Changes in MRP2 level. Human carcinoma cell lines
with increased levels of MRP2 are associated with
elevated cisplatin resistance, decreased intracellu-
lar accumulation of cisplatin, and decreased DNA
adduct formation [10].
The other mechanisms involved in Pt-resistance include
enhanced DNA repair capacity and increased antiapo-
ptotic activity. Nucleotide excision repair is the major
pathway for Pt adduct removal and repair of DNA
damage. The nucleotide excision repair complex is com-
posed of at least 17 proteins, but upregulation of only
a few rate-limiting proteins is necessary to increase the
excision repair capacity in resistant tumor cells, namely
XPA, ERCC1, topoisomerase II, and BRCA1. Downregu-
lation or gene mutation of the DNA damage recogni-
tion proteins (e.g. mismatch repair complex and p53)
may enhance the replicative bypass pathway and cause
post-replication DNA repair or DNA damage tolerance.
The factors involving increased antiapoptotic activity
include downregulation of the proapoptotic molecules
Taiwan J Obstet Gynecol • September 2009 • Vol 48 • No 3242
F.S. Liu
Bax or Bad, increased expression of the antiapoptotic
molecules Bcl-2 or Bcl-xL, overexpression of the apoptotic
inhibitor survivin, and suppressed activity of the direct
effectors of apoptosis, i.e. caspases 3, 8 and 9 [12].
Cancer Stem Cells and Chemotherapeutic
Drug Resistance
The cancer stem cell hypothesis states that the cancer-
initiating cell is a transformed tissue stem cell, which is
spared along with its normal tissue stem cell counter-
parts with very subtle differences. One of the defining
characteristics of normal tissue stem cells is their consti-
tutive resistance to environmental toxins, including most
chemotherapeutic agents. The constitutive drug resis-
tance of normal tissue stem cells is mediated by MDR
transporters and detoxifying enzymes. Cancer stem cells
also retain the essential property of self-protection
through the activity of MDR transporters [15].
Cancer stem cells have been identified in leukemias
and some solid tumors. Many researchers now suspect
that all cancers are composed of a mixture of stem cells
and proliferative cells. These cancer stem cells make up
as few as 1% of the total tumor cells, making them dif-
ficult to detect and study. Therefore, the existence of
cancer stem cells provides a tumor reservoir that is the
source of disease recurrence and metastasis. ABCB1 and
ABCG2 genes are expressed in both normal stem cells
and most tumor stem cells [16]. Thus, the major bar-
rier to therapy is the quiescent tumor stem cell with
constitutive MDR. In fact, dose-limiting toxicities of
many antineoplastic agents occur precisely at drug con-
centrations that damage normal tissue stem cells. If the
proposed relationships between normal and neoplas-
tic stem cells prove correct, the inescapable conclusion
is that systemic cytotoxic therapies are doomed to fail-
ure because regimens that spare resting normal stem
cells will also likely spare resting tumor stem cells [15].
Similarly, inhibition of drug transporters may also cause
toxicity of the patient’s normal stem cells, particularly
those of the bone marrow [16]. Successful therapy
awaits the discernment of biological and immunologic
differences between the tumor and normal stem cells
so that approaches can be developed to eliminate the
tumor stem cells without excessive toxicity to normal
stem cells.
Conclusion
Chemotherapeutic drug resistance is a major 
obstacle in cancer therapy. Although the three MDR
transporters have been recognized for decades and
their operating mechanisms have been extensively
studied, development of inhibitors of these trans-
porters is still clinically unsuccessful. The more com-
plicated mechanisms involved in the resistance to
Pt-based anticancer agents make it more difficult to
surmount. In addition to searching for potential MDR
transporter inhibitors, another important strategy in
cancer treatment is to ascertain the subtle differences
between normal and tumor stem cells in order to
develop therapies specifically targeting the cancer
stem cell while avoiding damage to the normal tissue
stem cell.
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